J. Bogers

发表

Interaction of St John's wort (Hypericum perforatum) with clozapine.

Annelies C P Van Strater, J. Bogers, 2012, International clinical psychopharmacology.

Compulsory treatment with clozapine: a retrospective long-term cohort study.

D. Cohen, P. Schulte, J. Bogers, 2007, International journal of law and psychiatry.

The incidence and economic impact of aggression in closed long-stay psychiatric wards

E. Giltay, A. V. van Hemert, W. B. van den Hout, 2020, International journal of psychiatry in clinical practice.

Diagnostic value of a simplified screening test for metabolic syndrome in a Dutch patient cohort with schizophrenia spectrum disorders

J. Selten, E. van der Ven, J. Bogers, 2018, Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists.

Oral contraceptives raise plasma clozapine concentrations.

J. Bogers, Dorinde E Bookholt, 2014, Journal of clinical psychopharmacology.

Low levels of vitamin D poorly responsive to daylight exposure in patients with therapy-resistant schizophrenia

T. Broekman, J. Bogers, T. Bostoen, 2016, Nordic journal of psychiatry.

Clozapine and COVID‐19 Vaccination: Effects on blood levels and leukocytes. An observational cohort study

D. Cohen, P. Schulte, J. Bogers, 2022, Acta psychiatrica Scandinavica.

Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia. A Meta-Analysis of Randomized Controlled Trials.

L. de Haan, J. Bogers, J. Vermeulen, 2022, Schizophrenia bulletin.

Tapering antipsychotic medication: practical considerations

W. Veling, L. de Haan, J. Moncrieff, 2021, Psychological Medicine.

COVID-19: Risks, Complications, and Monitoring in Patients on Clozapine

D. Cohen, P. Schulte, J. Bogers, 2021, Pharmacopsychiatry.

Delegating Clozapine Monitoring to Advanced Nurse Practitioners: An Exploratory, Randomized Study to Assess the Effect on Prescription and Its Safety

I. Sommer, Y. van der Zalm, M. Marcelis, 2020, Administration and Policy in Mental Health and Mental Health Services Research.

Add-on filgrastim during clozapine rechallenge unsuccessful in preventing agranulocytosis.

E. Giltay, J. Bogers, Andreia W P Hazewinkel, 2013, General hospital psychiatry.

Effects of multivitamin, mineral and n-3 polyunsaturated fatty acid supplementation on aggression among long-stay psychiatric in-patients: randomised clinical trial

J. J. Stolker, E. Giltay, A. V. van Hemert, 2022, BJPsych Open.

Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy.

Dan Cohen, D. Cohen, B. Bakker, 2012, The Journal of clinical psychiatry.

The incidence and economic impact of aggression in closed long-stay psychiatric wards

E. Giltay, A. V. van Hemert, W. B. van den Hout, 2020, International journal of psychiatry in clinical practice.

HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry

H. Stefánsson, D. Rujescu, E. Sigurdsson, 2021, Translational Psychiatry.

A Dutch Guideline for the Use of Clozapine

D. Cohen, B. Bakker, P. Schulte, 2010, The Australian and New Zealand journal of psychiatry.

Prescription and Underprescription of Clozapine in Dutch Ambulatory Care

I. Sommer, Y. van der Zalm, M. Marcelis, 2018, Front. Psychiatry.

Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial

F. Backx, W. Cahn, J. van os, 2021, BMC Psychiatry.

Feasibility and Effect of Increasing Clozapine Plasma Levels in Long-Stay Patients With Treatment-Resistant Schizophrenia

P. Schulte, T. Broekman, J. Bogers, 2023, Journal of clinical psychopharmacology.

Risk factors for psychotic relapse after dose reduction or discontinuation of antipsychotics in patients with chronic schizophrenia. A systematic review and meta-analysis.

L. de Haan, J. Bogers, J. Vermeulen, 2020, Schizophrenia bulletin.

Clozapine Underutilization in the Treatment of Schizophrenia: How Can Clozapine Prescription Rates Be Improved?

D. Cohen, B. Bakker, P. Schulte, 2016, Journal of clinical psychopharmacology.

Moving forward with clozapine

P. Schulte, J. Bogers, D. Cohen, 2020, Acta psychiatrica Scandinavica.

Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial

L. de Haan, P. Moleman, P. Schulte, 2018, European Neuropsychopharmacology.

Capillary compared to venous blood sampling in clozapine treatment: patients׳ and healthcare practitioners׳ experiences with a point-of-care device

Dan Cohen, D. Cohen, Jan P. A. M. Bogers, 2015, European Neuropsychopharmacology.

Clozapine and the risk of haematological malignancies.

D. Cohen, B. Bakker, J. Bogers, 2022, Lancet psychiatry.

Migration and dementia: a meta-analysis of epidemiological studies in Europe

B. Schmand, J. Selten, F. Termorshuizen, 2020, Psychological Medicine.

Differences between physicians' and nurse practitioners' viewpoints on reasons for clozapine underprescription

D. Cohen, J. Luykx, R. Kahn, 2019, Brain and behavior.

Schizophrenia among Surinamese in the Netherlands: high admission rates not explained by high emigration rates

J. D. de Jong, I. Komproe, J. Bogers, 2000, Psychological Medicine.

Genetic Susceptibility to Clozapine-Induced Agranulocytosis/Neutropenia Across Ethnicities: Results From a New Cohort of Turkish and Other Caucasian Participants, and Meta-Analysis

M. Babaoğlu, D. Cohen, J. Luykx, 2020 .

Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: Can the regulations be relaxed?

J. Bogers, S. Veerman, Dan Cohen, 2023, Schizophrenia Research.